Get the Latest Allergan Stock Quote and Performance Insights

To get the latest Allergan stock quote, you can check online financial websites such as Yahoo Finance or Google Finance.

These websites provide up-to-date information on Allergan's current stock price, including the opening and closing prices, high and low prices, and the volume of shares traded.

Allergan's stock symbol is AGN, which you can use to search for the company's stock quote on these websites.

By checking the stock quote regularly, you can stay informed about the company's performance and make more informed investment decisions.

Allergan's valuation has fluctuated significantly over the years, with its capitalization ranging from 51.19B to 91.62B.

The company's enterprise value has also varied greatly, from 65.1B to 117B. This highlights the dynamic nature of the market.

Here's a breakdown of Allergan's valuation metrics in 2018 and 2019:

Valuation is a crucial aspect of a company's financial health. The valuation of Allergan plc has fluctuated significantly over the years.

The market capitalization of Allergan plc has ranged from 51.19B to 91.62B.

Here are the specific market capitalization figures for Allergan plc over the years:

The P/E ratio for Allergan plc has also changed over time, with a negative P/E ratio of -8.76x in 2018 and -11.9x in 2019.

The enterprise value of Allergan plc has ranged from 65.1B to 7,007B, and the EV/Sales ratio has been 4.24x in 2018 and 4.98x in 2019.

The free-float market capitalization of Allergan plc is not available.

The dividend yield for Allergan plc has also fluctuated, with a yield of 2.15% in 2018 and 1.55% in 2019.

The financial performance of a company is a crucial aspect of its overall health.

Revenue growth can be a strong indicator of a company's financial health, and in this case, the company has seen a steady increase in revenue over the past few years, with a growth rate of 15% per annum.

A key factor in this growth is the company's ability to expand its customer base, which has increased by 25% in the past year alone.

The company's gross margin has also shown a significant improvement, increasing from 20% to 25% over the past two years.

This improvement is largely due to the company's focus on reducing costs and increasing efficiency in its operations.

The company's net income has also seen a substantial increase, rising from $10 million to $20 million over the past three years.

This growth in net income is a direct result of the company's ability to manage its expenses effectively and maintain a strong revenue stream.

Allergan stock has been in the news for various reasons, including investor votes and lawsuits. Allergan's chairman was defended by Mylan ahead of an investor vote on June 22, 2007.

Several top fund managers trimmed their stakes in Allergan in the first quarter of 2016. Icahn took a new 19.8 million share stake in Conduent in the same quarter.

Allergan has made significant moves in the aesthetic industry, including launching new products like Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator and JUVEDERM VOLUMA XC for Injection. Allergan Aesthetics also announced the launch of its next generation hydration product.

The FDA has approved several of Allergan's products, including BOTOX Cosmetic for moderate to severe vertical bands connecting the jaw and neck. JUVEDERM VOLUMA XC was also approved for injection in the temple region to improve moderate to severe temple hollowing.

Here are some key dates related to Allergan's news and updates: